ABSTRACT
dose of dapagliflozin 10 mg was not influenced by the concomitant administration of voglibose (0.2 mg t.i.d.). The geometric ratio (90% CI) for dapagliflozin AUC 0-inf with/without voglibose was 1.009 (0.954, 1.067), and for C max 1.040 (0.899, 1.204). The median time to C max (t max ) and plasma clearance of dapagliflozin were also similar between treatments. The mean half-life (t ) for dapagliflozin was slightly higher when administered in combination with voglibose.
Dapagliflozin 10 mg was well tolerated when administered alone and in combination with voglibose in Japanese patients with T2DM.
INTRODUCTION
The number of people diagnosed with diabetes worldwide has more than doubled since 1980 to nearly 350 million [1] . The rise in prevalence of diabetes has been particularly rapid in Japan and is likely to have been fueled by changes in lifestyle [2] .
In Japanese medical practice there is an increasing use of combination therapy with multiple antidiabetic drugs in the treatment of type 2 diabetes mellitus (T2DM) [3] .
Frequently an alpha-glucosidase inhibitor is a part of this treatment regimen. Voglibose is an oral antihyperglycemic agent of the alpha-glucosidase inhibitor class that is widely used in the management of T2DM in Japan [4] . Voglibose undergoes minimal systemic absorption and primarily functions within the gastrointestinal tract to decrease and delay the intestinal absorption of carbohydrate [5] [6] [7] .
Dapagliflozin is a first-in-class selective sodium-glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of T2DM that improves glycemic control by reducing the reabsorption of glucose in the kidney and enhancing the urinary excretion of excess glucose [8, 9] . As with voglibose, the mechanism of action of dapagliflozin is independent of insulin secretion or action and efficacy, and its safety has been evaluated in a broad range of patients with T2DM as a monotherapy [10, 11] and as an add-on to metformin, glimepiride, pioglitazone, sitagliptin, and insulin [11] [12] [13] [14] [15] [16] [17] . Both dapagliflozin and voglibose effectively control postprandial blood glucose excursions in patients with T2DM [18, 19] . Thus, the coadministration of dapagliflozin with voglibose could potentially provide a complementary approach to glycemic control.
Predictable dose-proportional pharmacokinetic and pharmacodynamic parameters with dapagliflozin have been demonstrated in both Japanese and non-Japanese subjects [20] [21] [22] Due to the differing pharmacokinetics of each treatment no drug-drug interaction was anticipated between dapagliflozin and voglibose. However, due to the possible future co-administration of dapagliflozin with voglibose in Japan, the aim of the study reported here was to assess the potential for drug-drug interaction between dapagliflozin and voglibose in Japanese patients with T2DM.
As voglibose is not orally absorbed, only the effect of voglibose on the plasma pharmacokinetics of dapagliflozin was studied. creatine kinase more than three-times the ULN.
MATERIALS AND METHODS

Subjects
Study Design
The study consisted of two pharmacokinetic sampling periods ( Fig. 1 methodology after solid phase extraction (Atlanbio). The lower limit of quantification of dapagliflozin in plasma was 1.0 ng/mL and the upper limit of quantification was 500.0 ng/mL. Run-to-run variability as described by between-run and within-run coefficients of variation (% CV) were 6.5 and 7.5, respectively.
Safety Assessments
Laboratory variables, vital signs, and 12-lead electrocardiogram (ECG) were monitored throughout the study. Adverse events (AEs)
were collected and summarized using the Medical Dictionary for Regulatory Activities (MedDRA version, version 14.0) vocabulary.
Statistical Analysis
All pharmacokinetic and safety data were summarized by dosing condition using descriptive statistics. The pharmacokinetic variables AUC and C max were log-transformed before analysis. They were analyzed using a mixed effect analysis of variance model, and log(C max ) was 0.095 and 0.2024, respectively. Two (10%) additional subjects were included to account for possible dropouts.
RESULTS
Subject Disposition and Demographics
All 22 patients enrolled in the study were Japanese. Thirteen of the patients were male and nine were female. The median age of the patients was 55 years and the median body mass index (BMI) was 25.7 kg/m 2 ( Table 1) .
Pharmacokinetics
The mean dapagliflozin plasma concentration- excluded from the evaluation of the AUC, plasma clearance and t due to the low reliability of the extrapolated portion of the AUC from the last measurable point to infinity i.e., the extrapolation ratio of AUC for the relevant subjects was [20%.
Safety
Dapagliflozin (10 mg) was found to be well tolerated by the subjects with T2DM in this study when administered alone or coadministered with voglibose. There were no serious adverse events, discontinuations of the investigational product due to adverse events, or any other significant adverse event in the study.
Five AEs (gingivitis, paresthesia oral, edema peripheral, bronchitis and pollakiuria) were Results from this study indicate that there is no clinically meaningful pharmacokinetic drug-drug interaction between dapagliflozin and voglibose in Japanese patients with T2DM.
The exposure to dapagliflozin (as measured by the AUC 0-inf and C max ) after a single oral dose of A potential limitation of the present study is that it was performed solely in patients of Japanese ethnicity. However, the results are still likely to be applicable to patients of other ethnicities, because voglibose has minimal systemic absorption from the gastrointestinal tract regardless of ethnicity and dapagliflozin shows similar pharmacokinetics in Japanese and non-Japanese subjects [20] [21] [22] .
It is interesting to speculate regarding the additional glycemic benefits that may be gained independent approach to glycemic control, which is likely to be associated with a low risk of hypoglycemia. In the present study no episodes of hypoglycemia were noted.
CONCLUSION
Both voglibose and dapagliflozin effectively control the rapid postprandial excursions observed following high carbohydrate meals [18, 19] 
